Isogenica Ltd Announces Collaboration with Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
22 March 2011 Isogenica Ltd today announced that it has executed a services agreement with Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (“J&JPRD”).
Isogenica licensed its CIS display technology to J&JPRD (as successor in business to Centocor Research & Development, Inc.) in 2008 for application with the J&JPRD’s Centyrin scaffold protein platform. This latest services agreement allows Isogenica to perform discovery work with the platform.
Isogenica’s CEO, Dr Kevin Matthews, said:
“We are delighted to partner on this opportunity. We have been working hard to make CIS display an ‘industrialised’ molecular biology tool and it is great to see the progress we have made rewarded with this latest collaboration.”
For further information please contact:
Kevin Matthews, CEO Isogenica
T: +44 (0)1799 533682
Isogenica specialises in the discovery and optimisation of therapeutic and diagnostic peptides, proteins and antibodies using its proprietary technology, CIS display. Founded in 2000 Isogenica has developed a unique capability in the field of protein engineering. Isogenica’s CIS display technology is an in vitro display technology that allows the rapid generation of polypeptide and antibody libraries from which it is possible to select lead molecules with high affinity and specificity for most targets.